Compare Illumina, Inc. (ILMN) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Xcel Energy Inc — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Xcel Energy Inc trades at $78.49 (market cap $49.11B). The key difference: Xcel Energy Inc is the larger of the two by market cap, and Xcel Energy Inc pays a 3.01% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | XEL | |
|---|---|---|
Market Cap | $27.94B | $49.11B |
Sector | Health | Utilities |
52-Week High | $194.33 | $83.91 |
52-Week Low | $91.00 | $71.14 |
Enterprise Value | $29.33B | $86.55B |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Xcel Energy (XEL) trades at $78.71, down 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $14.67 billion in 2025, with a net income margin of 14.14%. Recent news highlights a $60 billion capital plan through 2030 to support electrical demand growth from data centers and industrial expansion.
XEL presents a stable utility investment with a 62.96% analyst buy rating and a consensus price target of $93.86, implying 19% upside. Key opportunities include EPS growth projected at 9.6% annually through 2028, but risks involve regulatory pushback on rate increases and high debt levels with a debt-to-asset ratio of 41.64% in 2025. The stock's valuation at a P/E of 22.7 is reasonable for its growth outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
